2025-05-14 – Press Releases – www.prnewswire.com
– Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world’s first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. – The company has received the EOP2 meeting minutes, confirming the…
